BRCA2 and breast cancer: For BRCA2 PV carriers, RRM (at age 35 years), RRSO (at age 40 years), or both RRM (at age 35 years) and RRSO (at age 40 years) were cost-effective or cost-saving compared with high-risk BC surveillance and tamoxifen from age 30 years.